We are live on
!
Find out more
MB
MPM BioImpact Portfolio holdings
AUM
$1.64B
1-Year Est. Return
245.64%
This Fund
S&P 500
This Quarter
Est. Return
-24.96%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$373M
AUM Growth
-$176M
(-32%)
Cap. Flow
-$17M
Cap. Flow
% of AUM
-4.55%
Top 10 Holdings %
Top 10 Hldgs %
67.37%
Holding
38
New
5
Increased
4
Reduced
17
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$5.34M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$4.37M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
+$3.12M |
| 4 |
Relmada Therapeutics
RLMD
|
+$2.85M |
| 5 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LITS
Lite Strategy Inc
LITS
|
+$33M |
| 2 |
ITOS
iTeos Therapeutics
ITOS
|
+$3.59M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$367K |
| 4 |
Cytokinetics
CYTK
|
+$285K |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$265K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$1.4B
| $80.1M | 21.49% |
7,648,268
| – | – |
|
|
ITOS
2
DELISTED
iTeos Therapeutics
ITOS
| $56.2M | 15.08% |
1,745,943
-98,784
| -5% | -$3.59M |
|
|
MRUS
3
DELISTED
Merus
MRUS
| $24.3M | 6.52% |
919,482
-7,820
| -0.8% | -$210K |
|
|
RPTX
4
DELISTED
Repare Therapeutics
RPTX
| $23.4M | 6.27% |
1,639,849
| – | – |
|
|
HARP
5
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $15.9M | 4.26% |
319,671
| – | – |
|
6
Intellia Therapeutics
NTLA
$1.8B
| $11.6M | 3.11% |
159,409
-1,118
| -0.7% | -$94.7K |
|
7
Werewolf Therapeutics
HOWL
$45.8M
| $10.5M | 2.82% |
2,388,011
| – | – |
|
|
8
BioCryst Pharmaceuticals
BCRX
$2.51B
| $10.4M | 2.79% |
639,089
-22,862
| -3% | -$367K |
|
|
TPTX
9
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $9.43M | 2.53% |
351,350
+80,000
| +29% | +$2.69M |
|
|
TCRR
10
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $9.3M | 2.5% |
3,370,982
| – | – |
|
11
Geron
GERN
$970M
| $8.36M | 2.24% |
6,149,277
+525,388
| +9% | +$586K |
|
|
12
Cytokinetics
CYTK
$10B
| $8.25M | 2.22% |
224,246
-8,022
| -3% | -$285K |
|
|
13
Crinetics Pharmaceuticals
CRNX
$9B
| $8.05M | 2.16% |
366,676
-13,116
| -3% | -$265K |
|
14
Travere Therapeutics
TVTX
$6.19B
| $7.16M | 1.92% |
277,950
-9,943
| -3% | -$264K |
|
15
Harmony Biosciences
HRMY
$2.28B
| $6.69M | 1.8% |
137,517
-4,920
| -3% | -$201K |
|
|
GTHX
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $6.51M | 1.75% |
856,798
| – | – |
|
17
Mirum Pharmaceuticals
MIRM
$5.94B
| $6.35M | 1.71% |
288,531
-10,321
| -3% | -$211K |
|
|
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.9M | 1.58% |
+180,000
| New | +$5.34M |
|
|
YMAB
19
DELISTED
Y-mAbs Therapeutics
YMAB
| $5.27M | 1.41% |
443,702
-2,755
| -0.6% | -$28.3K |
|
|
20
Arcutis Biotherapeutics
ARQT
$2.99B
| $4.98M | 1.34% |
+258,500
| New | +$4.37M |
|
21
ADC Therapeutics
ADCT
$146M
| $4.91M | 1.32% |
334,384
-3,012
| -0.9% | -$47.8K |
|
|
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
| $4.69M | 1.26% |
495,603
-17,730
| -3% | -$166K |
|
23
Verastem
VSTM
$654M
| $4.58M | 1.23% |
270,388
-2,240
| -0.8% | -$38.6K |
|
|
ONCR
24
DELISTED
Oncorus, Inc.
ONCR
| $4.23M | 1.14% |
2,377,031
| – | – |
|
25
Axsome Therapeutics
AXSM
$10.4B
| $4.13M | 1.11% |
99,834
-3,571
| -3% | -$111K |
|
Similar funds
OCM
LFS
TIM
AAG
MRG
EPW
TWM
MA
MPM BioImpact's Q1 2022 Portfolio in Review
As of Q1 2022, MPM BioImpact held 38 positions worth $373M, down 32% from $549M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
MPM BioImpact withdrew a net $17M in Q1 2022, closing 1 position and reducing 17 holdings. Its most notable exit was Lite Strategy Inc, an estimated $33M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, MPM BioImpact opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $5.9M.
- MPM BioImpact's largest Q1 2022 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 180,000 shares worth $5.9M.
- MPM BioImpact added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2022, an estimated $2.69M increase.
- MPM BioImpact's biggest Q1 2022 reduction was iTeos Therapeutics, cutting an estimated $3.59M.
- MPM BioImpact fully exited Lite Strategy Inc in Q1 2022, selling an estimated $33M.
- MPM BioImpact's ten largest holdings make up 67% of its $373M portfolio in Q1 2022.
- MPM BioImpact opened 5 new positions and closed 1 in Q1 2022.
- MPM BioImpact's portfolio value fell 32% quarter-over-quarter to $373M.
Based on MPM BioImpact's 13F filing for Q1 2022, filed 13 May 2022.